Next 10 |
home / stock / cslly / cslly news
2024-04-24 08:31:26 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics gains as EU backs kidney disease therapy Travere Therapeutics Q4...
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
2024-03-28 05:42:57 ET Akebia Therapeutics ( NASDAQ: AKBA ) shares surged over 25% premarket on Thursday after the U.S. Food and Drug Administration (FDA) approved its Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adult patients o...
2024-03-20 12:11:15 ET More on Kyowa Kirin Kyowa buyout Orchard wins FDA nod for rare disease therapy Historical earnings data for Kyowa Kirin Dividend scorecard for Kyowa Kirin Financial information for Kyowa Kirin Read the full article on Seeking ...
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure Canada NewsWire ST. GALLEN, SWITZERLAND , March 19, 2024 /CNW/ -- CSL Vifor today a...
2024-03-07 13:29:15 ET More on AstraZeneca, CSL, etc. Sanofi (SNY) TD Cowen 44th Annual Health Care Conference (Transcript) GSK Plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgr...
2024-03-07 09:19:59 ET More on CSL CSL Limited: Earnings Beat Doesn't Mask Unfavorable Trial Results (Downgrade) CSL Limited (CSLLY) Q2 2024 Earnings Call Transcript CSL Limited falls after Phase 3 setback for key trial Historical earnings data for CSL ...
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season PR Newswire SUMMIT, N.J. , March 6, 2024 /PRNewswire/ -- CSL Seqirus, a glob...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure Canada NewsWire ST. GALLEN, SWITZERLAND , March 19, 2024 /CNW/ -- CSL Vifor today a...